Destiny Pharma (LON:DEST) Shares Down 30.1%

Shares of Destiny Pharma plc (LON:DEST) traded down 30.1% during trading on Tuesday . The stock traded as low as GBX 2.55 ($0.03) and last traded at GBX 3 ($0.04). 4,179,453 shares were traded during mid-day trading, an increase of 484% from the average session volume of 715,908 shares. The stock had previously closed at GBX 4.29 ($0.06).

Wall Street Analyst Weigh In

Separately, Shore Capital restated a “house stock” rating on shares of Destiny Pharma in a research report on Monday, July 15th.

Destiny Pharma Price Performance

The firm has a market capitalization of £2.87 million, a PE ratio of -50.00 and a beta of 0.22. The business has a 50-day simple moving average of GBX 3.14 and a 200-day simple moving average of GBX 13.12.

Insider Activity at Destiny Pharma

In related news, insider Nigel Rudd purchased 1,240,000 shares of Destiny Pharma stock in a transaction that occurred on Friday, August 2nd. The shares were bought at an average price of GBX 0.25 ($0.00) per share, with a total value of £3,100 ($4,151.04). 25.94% of the stock is currently owned by insiders.

About Destiny Pharma

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria.